Audited Financial Results For The Quarter And Year Ended March 31, 2026 And Declaration of Final Dividend for the financial year ended March 31, 2026, is attached
DRAGARWQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 2.4 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr Agarwal's Eye Hospital reported FY26 revenue of Rs 470.87 crore, up 18.6% from Rs 397.15 crore in FY25, approaching but not reaching 20% revenue growth. Net profit after tax grew 28.3% to Rs 70.10 crore from Rs 54.65 crore, exceeding the 25% PAT growth signal threshold. EBITDA margin expanded slightly to 32% from 31%. The Board recommended a final dividend of Rs 4 per share (40%), which combined with the Rs 3 interim dividend already paid totals Rs 7 per share (70%) for FY26. The auditor issued an unmodified opinion confirming clean financials. The company also completed a Rs 70 crore preferential share issue to its holding company and has a pending amalgamation scheme with Dr Agarwal's Health Care Limited.
Strong profitability growth with 28% PAT increase and clean audit opinion are positive signals. The total 70% dividend payout demonstrates shareholder-friendly policy. Revenue growth of 18.6% shows solid expansion though slightly below 20% threshold.